Molecular Partners Ag -adr (MOLN)

$6.5

+0.6

(+10.17%)▲

Live

Performance

  • $6.07
    $6.53
    $6.50
    downward going graph

    6.62%

    Downside

    Day's Volatility :7.04%

    Upside

    0.46%

    downward going graph
  • $3.32
    $12.70
    $6.50
    downward going graph

    48.92%

    Downside

    52 Weeks Volatility :73.86%

    Upside

    48.82%

    downward going graph

Returns

PeriodMolecular Partners Ag -adrSector (Health Care)Index (Russel 2000)
3 Months
52.06%
6.5%
0.0%
6 Months
26.61%
7.1%
0.0%
1 Year
-5.67%
9.8%
0.0%
3 Years
-69.7%
14.2%
-20.2%

Highlights

Market Capitalization
219.3M
Book Value
$5.13
Earnings Per Share (EPS)
-2.0
Wall Street Target Price
8.97
Profit Margin
0.0%
Operating Margin TTM
-579.18%
Return On Assets TTM
-17.98%
Return On Equity TTM
-29.96%
Revenue TTM
6.7M
Revenue Per Share TTM
0.21
Quarterly Revenue Growth YOY
-10.2%
Gross Profit TTM
138.9M
EBITDA
-61.0M
Diluted Eps TTM
-2.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.23
EPS Estimate Next Year
-1.56
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    9%Buy
    27%Hold
    63%Sell
Based on 11 Wall street analysts offering stock ratings for Molecular Partners Ag -adr(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
3
3
3
Sell
7
7
7

Analyst Forecast

What analysts predicted

Upside of 38.0%

Current $6.50
Target $8.97

Company Financials

FY18Y/Y Change
Revenue
10.5M
↓ 48.27%
Net Income
-37.7M
↑ 45.64%
Net Profit Margin
-357.66%
↓ 230.61%
FY19Y/Y Change
Revenue
21.0M
↑ 96.84%
Net Income
-37.5M
↓ 2.02%
Net Profit Margin
-178.03%
↑ 179.63%
FY20Y/Y Change
Revenue
10.6M
↓ 54.16%
Net Income
-71.2M
↑ 72.96%
Net Profit Margin
-671.7%
↓ 493.67%
FY21Y/Y Change
Revenue
10.2M
↓ 0.15%
Net Income
-69.8M
↑ 1.63%
Net Profit Margin
-683.65%
↓ 11.95%
FY22Y/Y Change
Revenue
189.6M
↑ 1931.68%
Net Income
117.9M
↓ 284.77%
Net Profit Margin
62.17%
↑ 745.82%
FY23Y/Y Change
Revenue
8.4M
↓ 96.29%
Net Income
-73.7M
↓ 152.59%
Net Profit Margin
-880.7%
↓ 942.87%
Q4 FY22Q/Q Change
Revenue
2.7M
↑ 15.23%
Net Income
-19.9M
↑ 66.54%
Net Profit Margin
-739.14%
↓ 227.72%
Q1 FY23Q/Q Change
Revenue
3.3M
↑ 13.26%
Net Income
-16.8M
↓ 23.02%
Net Profit Margin
-502.39%
↑ 236.75%
Q2 FY23Q/Q Change
Revenue
463.4K
↓ 86.39%
Net Income
-17.9M
↑ 4.33%
Net Profit Margin
-3.9K%
↓ 3349.9%
Q3 FY23Q/Q Change
Revenue
2.5M
↑ 512.29%
Net Income
-11.4M
↓ 28.45%
Net Profit Margin
-450.18%
↑ 3402.11%
Q4 FY23Q/Q Change
Revenue
1.2M
↓ 59.39%
Net Income
-23.5M
↑ 72.92%
Net Profit Margin
-1.9K%
↓ 1466.49%
Q1 FY24Q/Q Change
Revenue
3.0M
↑ 165.31%
Net Income
-12.6M
↓ 42.75%
Net Profit Margin
-413.62%
↑ 1503.05%
FY18Y/Y Change
Total Assets
157.7M
↑ 7.43%
Total Liabilities
64.5M
↑ 129.12%
FY19Y/Y Change
Total Assets
108.3M
↓ 32.37%
Total Liabilities
52.4M
↓ 19.95%
FY20Y/Y Change
Total Assets
212.7M
↑ 78.73%
Total Liabilities
91.1M
↑ 58.13%
FY21Y/Y Change
Total Assets
189.0M
↓ 7.93%
Total Liabilities
71.6M
↓ 18.61%
FY22Y/Y Change
Total Assets
262.3M
↑ 51.89%
Total Liabilities
27.1M
↓ 58.56%
FY23Y/Y Change
Total Assets
235.7M
↓ 24.37%
Total Liabilities
26.1M
↓ 19.08%
Q4 FY22Q/Q Change
Total Assets
262.3M
↓ 6.72%
Total Liabilities
27.1M
↓ 8.87%
Q1 FY23Q/Q Change
Total Assets
267.7M
↓ 6.76%
Total Liabilities
24.5M
↓ 17.43%
Q2 FY23Q/Q Change
Total Assets
257.4M
↓ 5.74%
Total Liabilities
27.4M
↑ 9.59%
Q3 FY23Q/Q Change
Total Assets
218.1M
↓ 5.37%
Total Liabilities
21.9M
↓ 10.63%
Q4 FY23Q/Q Change
Total Assets
235.7M
↓ 9.06%
Total Liabilities
26.1M
↑ 0.06%
Q1 FY24Q/Q Change
Total Assets
206.1M
↓ 6.43%
Total Liabilities
18.9M
↓ 22.18%
FY18Y/Y Change
Operating Cash Flow
-43.2M
↑ 6.13%
Investing Cash Flow
9.8M
↓ 53.93%
Financing Cash Flow
398.5K
↓ 50.94%
FY19Y/Y Change
Operating Cash Flow
-1.2M
↓ 97.2%
Investing Cash Flow
-20.5M
↓ 306.35%
Financing Cash Flow
-234.4K
↓ 157.91%
FY20Y/Y Change
Operating Cash Flow
-32.9M
↑ 2337.59%
Investing Cash Flow
-24.7M
↑ 9.63%
Financing Cash Flow
128.4M
↓ 49968.72%
FY21Y/Y Change
Operating Cash Flow
-99.5M
↑ 213.81%
Investing Cash Flow
-24.3M
↑ 2.26%
Financing Cash Flow
55.4M
↓ 55.32%
FY22Y/Y Change
Operating Cash Flow
118.6M
↓ 230.36%
Investing Cash Flow
-101.1M
↑ 354.74%
Financing Cash Flow
-1.6M
↓ 103.1%
Q4 FY22Q/Q Change
Operating Cash Flow
-14.3M
↓ 21.42%
Investing Cash Flow
35.9M
↓ 230.94%
Financing Cash Flow
-298.0K
↓ 67.71%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.1M
↑ 15.97%
Investing Cash Flow
4.4M
↓ 88.76%
Financing Cash Flow
-325.2K
↓ 0.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.8M
↓ 19.72%
Investing Cash Flow
4.5M
↑ 0.0%
Financing Cash Flow
-306.0K
↓ 7.74%
Q3 FY23Q/Q Change
Operating Cash Flow
-13.2M
↓ 0.67%
Investing Cash Flow
17.8M
↑ 340.5%
Financing Cash Flow
-298.0K
↑ 8.76%

Technicals Summary

Sell

Neutral

Buy

Molecular Partners Ag -adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Molecular Partners Ag -adr
Molecular Partners Ag -adr
-19.34%
26.61%
-5.67%
-69.7%
-69.06%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Molecular Partners Ag -adr
Molecular Partners Ag -adr
1.71
NA
NA
-2.23
-0.3
-0.18
NA
5.13
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Molecular Partners Ag -adr
Molecular Partners Ag -adr
Sell
$219.3M
-69.06%
1.71
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Molecular Partners Ag -adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.03M → 2.73M (in $), with an average increase of 62.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -19.78M → -11.32M (in $), with an average increase of 74.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 67.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 256.2%

Institutional Holdings

  • Bvf Inc

    1.35%

  • Suvretta Capital Management, LLC

    1.22%

  • TANG CAPITAL MANAGEMENT LLC

    0.30%

Company Information

Organization
Molecular Partners Ag -adr
Employees
167
CEO
Dr. Patrick Amstutz Ph.D.
Industry
Services

Discover More

FAQs